Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

74 results about "Constant domain" patented technology

Antibodies comprising chimeric constant domains

Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.
Owner:REGENERON PHARMACEUTICALS INC

Antibodies comprising modified heavy chain constant regions

To provide antibodies including modified heavy chain constant regions, which are heavy chain constant regions (referred to as "modified heavy chain constant regions") or functionally equivalent fragments thereof that enhance biological properties of antibodies relative to the same antibodies in unmodified form.SOLUTION: An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.SELECTED DRAWING: None
Owner:BRISTOL MYERS SQUIBB CO

Immunoglobulin single variable domains targeting t cell receptor

The present technology provides immunoglobulin single variable domains (ISVDs) binding both the constant domain of a human T cell receptor (TCR) on a T cell and the constant domain of a non-human primate TCR on a T cell. It also relates to polypeptides comprising an ISVD according to the present technology and at least one ISVD capable of binding to an antigen on a target cell. The present technology further provides nucleic acids encoding said ISVDs or polypeptides as well as vectors, hosts and methods to produce these ISVDs or polypeptides. Moreover, the present technology relates to methods for treatment making use of the ISVDs or polypeptides of the present technology.
Owner:ABLYNX NV +1

Precision activated polypeptides

The present technology provides polypeptides comprising a first immunoglobulin single variable domain (ISVD) binding to albumin, a second ISVD capable of binding to both the constant domain of a human T cell receptor (TCR) on a T cell and the constant domain of a non-human primate TCR on a T cell, wherein said first and second ISVD are linked by a protease cleavable linker, and a targeting moiety. The present technology further provides nucleic acids encoding said polypeptides as well as vectors, hosts and methods to produce these polypeptides. Moreover, the present technology relates to methods for treatment making use of the polypeptides according to the present technology.
Owner:ABLYNX NV

Screening methods

The invention relates to screening methods. In particular, it relates to a method of identifying a functional TCR from a library of particles, which displays a plurality of different T cell receptors (TCRs). The method may comprise a) exposing the library of particles to a target antigen to identify TCRs that bind to the target antigen, b) transfecting a plurality of T cells with nucleic acid encoding TCRs identified in step (a), c) exposing the plurality of transfected cells to the target antigen, and d) selecting cells having TCR activity in the presence of the target antigen. Transfection of the T cells is such that each T cell comprises a nucleic acid encoding a single TCR from the library of particles, the nucleic acid is integrated into the genome of the T cell at a single identical pre-defined locus, and the TCR is in a single chain format and comprises an alpha chain variable domain, a beta cain variable domain and a constant domain. The T cells do not express endogenous TCR. A T-cell comprising a recombinase mediated landing pad, wherein the T cell constitutively expresses TCR constant domain and does not express endogenous TCR, is also claimed.
Owner:IMMUNOCORE LTD

Chimeric heavy chain constant domains with reduced binding to FC gamma receptors and uses thereof

The present disclosure relates to chimeric heavy chain constant domains with reduced effector function. Also disclosed are recombinant polypeptides comprising such chimeric heavy chain constant domains, including antibodies such as multispecific antibodies, fusion proteins, and other recombinant proteins. Also disclosed are nucleic acids encoding such recombinant polypeptides, as well as cells expressing such recombinant polypeptides and pharmaceutical compositions comprising such recombinant polypeptides.
Owner:REGENERON PHARMACEUTICALS INC

Half-life modulation by a tag comprising at least one constant domain of an immunoglobulin light chain

The present invention provides a method of modulating a molecular mass of a fusion polypeptide, wherein the fusion polypeptide comprises a target polypeptide fused to a tag suitable for affinity purification or detection of the target polypeptide, wherein the tag comprises at least one constant domain of an immunoglobulin light chain or orthologous polypeptide or fragment thereof and wherein the molecular mass and / or an isoelectric point of the fusion polypeptide is modulated by increasing the molecular mass of the tag via combining the one constant domain of an immunoglobulin light chain or orthologous polypeptide or fragment thereof with one or more further constant domain(s) of an immunoglobulin light chain or orthologous polypeptide(s) or fragment(s) thereof; wherein the constant domain of the immunoglobulin light chain or orthologous polypeptide or fragment thereof of the tag is monomeric; and wherein optionally the target polypeptide is fused to the tag via a first linker. The invention further provides a fusion polypeptide obtained or obtainable by this method. The invention also provides a tag and a fusion polypeptide comprising the tag.
Owner:TECHNISCHE UNIVERSITAET MUENCHEN IN VERTRETUNG DES FREISTAATES BAYERN

Multispecific antibodies recognising human serum albumin, TCR and a tumor antigen recognising moiety

The present technology provides polypeptides comprising a first immunoglobulin single variable domain (ISVD) binding to albumin, a second ISVD capable of binding to both the constant domain of a human T cell receptor (TCR) on a T cell and the constant domain of a non-human primate TCR on a T cell, wherein said first and second ISVD are linked by a protease cleavable linker, and a targeting moiety. The present technology further provides nucleic acids encoding said polypeptides as well as vectors, hosts and methods to produce these polypeptides. Moreover, the present technology relates to methods for treatment making use of the polypeptides according to the present technology.
Owner:ABLYNX NV

Mice that make heavy chain antibodies

Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion in an immunoglobulin constant region CH1 gene (optionally a deletion in a hinge region) of an IgG, IgA, IgD, and / or IgE, and wherein the mouse is capable of expressing a functional IgM. Genetically modified mice are described, including mice having a functional IgM gene and modified to have a deletion of a CH1 domain and a hinge region in a heavy chain constant domain that is not an IgM, e.g., in an IgG heavy chain constant domain. Genetically modified mice that make human variable / mouse constant chimeric heavy chain antibodies (antibodies that lack a light chain), fully mouse heavy chain antibodies, or fully human heavy chain antibodies are provided.
Owner:REGENERON PHARMACEUTICALS INC

Antibody molecules that bind PD-l1 and CD137

The present application relates to antibody molecules that bind both PD-L1 and CD137 and are able to induce agonism of CD137. The antibody molecules comprise a CDR-based binding site for PD-L1, and a CD137 antigen-binding site that is located in a constant domain of the antibody molecule. The antibody molecules of the invention find application, for example, in the treatment of diseases, such as cancer.
Owner:INVOX PHARMA LTD

Antibody molecules that bind PD-l1 and CD137

The present application relates to antibody molecules that bind both PD-L1 and CD137 and are able to induce agonism of CD137. The antibody molecules comprise a CDR-based binding site for PD-L1, and a CD137 antigen-binding site that is located in a constant domain of the antibody molecule. The antibody molecules of the invention find application, for example, in the treatment of diseases, such as cancer.
Owner:INVOX PHARMA LTD

Antigen-binding molecules comprising unpaired variable domains

To provide single variable domain antibodies that can be used as pharmaceutical products.SOLUTION: The invention relates to antibodies comprising unpaired variable domains, e.g., heavy chain variable (VH) domains, for binding antigen. The invention relates also to antibodies comprising two immunoglobulin (Ig) chains, where a first Ig chain comprises a variable domain and a constant domain, and a second Ig chain comprises a constant domain, and the second Ig chain lacks a variable domain thereby leaving the variable domain of the first Ig chain unpaired.SELECTED DRAWING: None
Owner:KYMBA LIMITED

Heterodimeric proteins

To provide heterodimeric antibodies that solve co-engagement of antigens in a multivalent manner which is a drawback of bispecific antibodies built with full length antibody-like formats.SOLUTION: In one aspect, the present invention discloses heterodimeric antibodies each comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen-binding domain, and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc domain and a second antigen-binding domain. In an additional aspect the heterodimeric antibody comprises a first monomer comprising a heavy chain comprising a first Fc domain and a single chain Fv region (scFv) that binds a first antigen, where the scFv comprises a charged scFv linker. The heterodimeric antibody further comprises a second monomer comprising a first heavy chain comprising a second Fc domain and a first variable heavy chain and a first light chain.SELECTED DRAWING: Figure 1-1
Owner:XENCOR INC

Multifunctional molecules that bind to T cell-associated cancer cells and their uses

Disclosed are multifunctional molecules, including i) an antigen binding domain that binds to a T cell receptor β chain constant domain 1 or a T cell receptor β chain constant domain 2; and one, two or all of the following: (ii) an immune cell connector (e.g., selected from NK cell connectors, T cell connectors, B cell connectors, dendritic cell connectors or macrophage connectors); (iii) a cytokine molecule or a cytokine inhibitor molecule; (iv) a death receptor signal enhancer; and / or (v) a matrix modification portion. In addition, disclosed are nucleic acids encoding the multifunctional molecules, methods for producing the above molecules, and methods for treating cancer using the above molecules.
Owner:MARENGO THERAPEUTICS INC

Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof

Non-human animals (and / or non-human cells) and methods of using the same are provided, which non-human animals (and / or non-human cells) have a genome comprising human antibody-encoding sequences (i.e., immunoglobulin genes). Non-human animals described herein express antibodies that are of IgA, IgD, or IgM isotypes. Non-human animals provided herein are, in some embodiments, characterized by expression of IgA antibodies that contain human heavy chain and light chain variable domains and rodent constant domains. Methods for producing antibodies from non-human animals are also provided, which antibodies contain human variable regions and rodent constant regions.
Owner:REGENERON PHARMACEUTICALS INC

Antibodies with functional domains in the elbow region between variable and constant domain

The present invention provides engineered antibodies and antigen binding fragments, in which an additional functional domain is inserted into the elbow region of the antibody or antigen binding fragment. The present invention also provides nucleic acid molecules, such as vectors, encoding such antibodies and antigen binding fragments, host cells and compositions comprising such antibodies, antigen binding fragments or nucleic acid molecules and uses thereof. For example a multispecific antibody format is provided, in which an additional binding site (specificity) is inserted into the elbow region of an antibody or antigen binding fragment.
Owner:INSTITUTE FOR RESEARCH IN BIOMEDICINE

Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof

Non-human animals (and / or non-human cells) and methods of using the same are provided, which non-human animals (and / or non-human cells) have a genome comprising human antibody-encoding sequences (i.e., immunoglobulin genes). Non-human animals described herein express antibodies that are of IgA, IgD, or IgM isotypes. Non-human animals provided herein are, in some embodiments, characterized by expression of IgA antibodies that contain human heavy chain and light chain variable domains and rodent constant domains. Methods for producing antibodies from non-human animals are also provided, which antibodies contain human variable regions and rodent constant regions.
Owner:REGENERON PHARMACEUTICALS INC

Modified Fc region

The present invention relates to the field of modified constant domains of canine or feline antibodies with altered immune effector functions and uses thereof. More specifically, the present application relates to modified Fc fragments with significantly reduced FcyRI and Clq binding.
Owner:ZOETIS SERVICES LLC

Multi Variable Domain Therapeutic Immunoglobulin

This disclosure relates to an immunoglobulin molecule having multiple variable domains that are each specific for a receptor, as well as heterodimeric molecules that include the multivariable domain immunoglobulin and a second heavy chain constant domain (HCCD2) of an antibody comprising a CH1 and a second Fc region (FC2), where FC1 and FC2 heterodimerize.
Owner:TENTARIX BIOTHERAPEUTICS INC

Materials and methods for improved bioengineered pairing of antigen-binding variable regions

PendingJP2025525530AFungiHybrid immunoglobulinsHistocompatibility Antigens Class IHeavy chain
Antigen-binding molecules engineered to replace the light chain constant domain (CL) and heavy chain constant domain 1 (CH1) with HLA class I histocompatibility antigen alpha chain-E alpha-3 (HLA-E) / beta2 microglobulin (B2M) or intercellular adhesion molecule 1 domain 1 (ICAM-1 D1) / ICAM-1 D1 dimerization domain are described.
Owner:JANSSEN BIOTECH INC

Common light chain mouse

A genetically modified mouse is provided, wherein the mouse is incapable of rearranging and expressing an endogenous mouse immunoglobulin light chain variable sequence, wherein the mouse expresses only one or two human light chain variable domains encoded by human immunoglobulin sequences operably linked to the mouse kappa (κ) constant gene at the endogenous mouse κ locus, wherein the mouse expresses a reverse chimeric antibody having a light chain variable domain derived from one of only two human light chain variable region gene segments and a mouse κ constant domain, and a human heavy chain variable domain and a mouse heavy chain constant domain, from an endogenous mouse heavy chain locus. Bispecific epitope-binding proteins that are fully human are provided, comprising two different heavy chains that associate with an identical light chain that comprises a variable domain derived from one of two different human light chain variable region gene segments.
Owner:REGENERON PHARMACEUTICALS INC

Trangenic rodents for cell line identification and enrichment

The disclosure provides nucleic acid constructs comprising a transmembrane reporter cassette encoding an affinity tag, a transmembrane (TM) domain and a fluorescent reporter protein. In embodiments, the nucleic acid constructs are inserted in a safe harbor locus or an immunoglobulin constant domain locus of in a cell of a non-human mammal. In embodiments, when the transmembrane reporter cassette is expressed in the cell, the affinity tag is displayed on a surface of the cell while the fluorescent reporter protein is located inside the cell membrane. The presence of the affinity tag and the fluorescent reporter protein allow for identification, sorting and / or isolation of cells expressing the nucleic acid constructs. The disclosure also provides embodiments of methods of modifying cells and non-human organisms with the nucleic acid constructs, along with embodiments of cells and non-human organisms produced using the disclosed methods.
Owner:ABCELLERA BIOLOGICS INC

Heterodimeric proteins

In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc domain and a second antigen binding domain. In an additional aspect the heterodimeric antibody comprises a first monomer comprising a heavy chain comprising a first Fc domain and a single chain Fv region (scFv) that binds a first antigen, wherein the scFv comprises a charged scFv linker. The heterodimeric antibody further comprises a second monomer comprising a first heavy chain comprising a second Fc domain and a first variable heavy chain and a first light chain.
Owner:XENCOR INC

Multifunctional molecules that bind to T cell related cancer cells and uses thereof

Multifunctional molecules that include i) an antigen binding domain that binds to a T cell receptor beta chain constant domain 1 or T cell receptor beta chain constant domain 2; and one, two or all of: (ii) an immune cell engager (e.g., chosen from an NK cell engager, a T cell engager, a B cell engager, a dendritic cell engager, or a macrophage cell engager); (iii) a cytokine molecule or cytokine inhibitor molecule; (iv) a death receptor signal enhancer; and / or (v) a stromal modifying moiety are disclosed. Additionally disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.
Owner:MARENGO THERAPEUTICS INC

Antibodies binding to constant domains of gamma delta t-cell receptors

This invention relates to human antibodies and antigen-binding fragments thereof that specifically bind to one or more constant domains of a gamma delta T-cell receptor (gdTCR) or a fragment or fragments thereof. The invention also relates to novel recombinant antigens, particularly novel recombinant and / or isolated antigens comprising one or more constant domains of a gamma delta T- cell receptor (gdTCR) or a fragment or fragments thereof and antibodies that bind said antigens. Further, this invention relates to methods employing said recombinant antigens to obtain said antibodies that specifically bind to and selectively target the constant regions of a gdTCR or fragment thereof. This invention additionally relates to methods for producing and purifying said antibodies and recombinant antigens. Additionally, this invention relates to polynucleotide molecules encoding said antibodies and said recombinant antigens. It also relates to vectors containing such polynucleotides and host cells comprising such polynucleotides and methods of producing said antibodies and antigen- binding fragments. The invention also relates to methods using said antibodies, such as methods of detecting, diagnosing and treating disease using said antibodies and medicaments comprising or derived from said antibodies.
Owner:CYTOSPIRE THERAPEUTICS LTD